低淋巴细胞与单核细胞比值在高肿瘤负荷滤泡性淋巴瘤中独立相关于早期复发(POD24):RELEVANCE亚组分析
基于RELEVANCE试验中1018例既往未治疗的高肿瘤负荷滤泡性淋巴瘤患者,中位淋巴细胞与单核细胞比值(LMR)为2.5(范围0.3-93.5),LMR≤2与更短的无进展生存(HR=1.39,p=0.002)和总生存(HR=1.44,p=0.049)相关,并与治疗开始后24个月内疾病进展(POD24)风险升高相关(多因素OR=1.58,p=0.02)。
要点
- LMR≤2见于37%(372/1018)的高肿瘤负荷滤泡性淋巴瘤患者,且与更晚年龄和更高危疾病相关。
- LMR≤2与更短无进展生存(HR=1.39,p=0.002)和总生存(HR=1.44,p=0.049)相关。
- LMR≤2与POD24风险升高相关(单因素OR=1.84,p<0.001;多因素OR=1.58,p=0.02)。
核心结论
- LMR是易于获取的参数,可提供需治疗滤泡性淋巴瘤患者的结局信息,在低危患者中尤其有帮助。
- 是否加入来那度胺等免疫调节剂可降低其不良预后价值需进一步研究。
研究设计与样本
- RELEVANCE试验的亚组分析,纳入1018例既往未治疗的高肿瘤负荷滤泡性淋巴瘤患者。
主要发现
- 中位LMR为2.5(范围0.3-93.5),LMR≤2患者372例(37%),该组患者更年长且疾病风险更高。
- LMR≤2与更短无进展生存相关(HR=1.39,p=0.002)。
- LMR≤2与更短总生存相关(HR=1.44,p=0.049)。
- LMR与无进展生存的关联在利妥昔单抗联合化疗组显著(p=0.01),在利妥昔单抗联合来那度胺组不确定(p=0.08)。
- 在三个滤泡性淋巴瘤国际预后指数风险类别中,LMR仅在低危组保留与无进展生存的关联(p=0.03)。
局限性
- 是否加入来那度胺等免疫调节剂可降低LMR的不良预后价值需进一步研究。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The peripheral blood lymphocyte-to-monocyte ratio (LMR) has been shown to predict outcomes in follicular lymphoma (FL). Among 1018 patients from the RELEVANCE trial (for previously untreated, high tumour burden FL), the median LMR was 2.5 (range, 0.3-93.5) and an LMR cut-off of 2 was mostly associated with survival end-points. Patients with an LMR ≤2 (n = 372; 37%) were older and had higher risk disease. An LMR ≤2 was associated with a shorter progression-free survival (PFS) (hazard ratio [HR] = 1.39, p = 0.002) and overall survival (OS) (HR = 1.44, p = 0.049). The association of the LMR with PFS was significant in the rituximab plus chemotherapy arm (p = 0.01) and inconclusive in the rituximab plus lenalidomide arm (p = 0.08). Within the three Follicular Lymphoma International Prognostic Index risk categories, the LMR retained its association with PFS only in the low-risk group (p = 0.03). An LMR ≤2 was also associated with a higher risk of progression of disease within 24 months of treatment initiation (univariable odds ratio (OR) = 1.84, p < 0.001; multivariable OR = 1.58, p = 0.02). In conclusion, the LMR is an easily accessible parameter informative of outcomes in FL patients in need of treatment, being especially helpful in otherwise low-risk patients. Whether the incorporation of immunomodulators such as lenalidomide will reduce its negative prognostic value needs to be further investigated.
引用
- Mozas P, Ould Ammar R, Chartier L, et al. A low lymphocyte-to-monocyte ratio is independently associated with early relapse (POD24) in high tumour burden follicular lymphoma: A RELEVANCE subanalysis. Br J Haematol. 2025. PMID: 40031898. doi:10.1111/bjh.20038
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。